NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Intensity-Modulated Radiotherapy for treatment of Prostate Cancer

Response to consultee and commentator comments on the matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed:						
Provisional matrix of consultees and commentators sent for consultation						
Summary of comments, action taken, and justification of action:						
	Proposal: Proposal made by: Action taken: Removed/Added/Not included/Noted Justification:					
1.	Consultees should include manufacturers of both IMRT and SRS systems.	Accuray				

National Institute for Health and Clinical Excellence

Response to comments on the matrix of consultees and commentators (pre-referral) for the appraisal of Intensity-Modulated Radiotherapy for treatment of Prostate Cancer

2.	Consultees should include	Elekta		
	Medical Physics groups,			
	who will ultimately be			
	planning and performing			
	the QA for IMRT and also			
	Therapy Radiographers			
	who will actively deliver the			
	treatment to the patients.			
	We feel they should be			
	included in any consult in			
	the future as they are at the			
	"cutting edge" as it were.			
			<u> </u>	

Response to comments on the matrix of consultees and commentators (pre-referral) for the appraisal of Intensity-Modulated Radiotherapy for treatment of Prostate Cancer

3.	Some key groups/	Institute of Physics and Engineering in	Added	This organisation's interests are
	manufacturers have been	Medicine (IPEM)		closely related to the appraisal topic
	omitted from the matrix of			and as per our inclusion criteria and
	consultees and			equalities commitments. Therefore
	commentators. Most			the Society of Radiographers have
	significantly the Society of			been added to the matrix under
	Radiographers should be			'professional' groups
	included. In terms of			
	manufacturers the			
	independent treatment			
	planning system			
	manufacturers should be			
	included (Philips Medical			
	Systems, CMS and			
	Nucletron).			

Response to comments on the matrix of consultees and commentators (pre-referral) for the appraisal of Intensity-Modulated Radiotherapy for treatment of Prostate Cancer

4.	Consultees should include the Institute of Physics and Engineering in Medicine (IPEM) and the College of Radiographers SCOR.	NCRI Radiotherapy CSG (including co- ordinated comments from other relevant CSGs), Royal College of Radiologists, Royal College of Physicians, Joint Collegiate Council for Oncology and the Association of Cancer Physicians.	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Institute of Physics and Engineering in Medicine (IPEM) and the College of Radiographers SCOR.have been added to the matrix under 'professional' groups
5.	Prostate Cancer Support Federation should be added to patient groups on the matrix	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Prostate Cancer Support Federation have been added to the matrix under 'patient' groups

Response to comments on the matrix of consultees and commentators (pre-referral) for the appraisal of Intensity-Modulated Radiotherapy for treatment of Prostate Cancer

6.	Pro Cancer research fund should be added to research groups on the matrix	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Pro Cancer research fund have been added to the matrix under 'patient' groups
7.	Prostate Cancer Research Foundation should be added to the research groups on the matrix	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Prostate Cancer Research Foundation have been added to the matrix under 'research" groups

Response to comments on the matrix of consultees and commentators (pre-referral) for the appraisal of Intensity-Modulated Radiotherapy for treatment of Prostate Cancer

8.	Prostate Matters International should be added to the matrix – either in research groups or in professional groups	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore Prostate Matters International have been added to the matrix under 'research' groups
9.	St Peter's Trust for Kidney, Bladder and Prostate Research should be added to the research groups on the matrix	PPIP	Not added	This organisation are not a National Group, so therefore should not go on the matrix.

Response to comments on the matrix of consultees and commentators (pre-referral) for the appraisal of Intensity-Modulated Radiotherapy for treatment of Prostate Cancer

10.	The Ovarian and Prostate Cancer Research Trust should be added to the research groups on the matrix	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Ovarian and Prostate Cancer Research Trust have been added to the matrix under 'research" groups
11.	Prostate UK – should replace Prostate Research Campaign UK on the matrix	PPIP	Added	Prostate UK has replaced Prostate Research Campaign UK on the matrix, as the organisation has changed names.

Response to comments on the matrix of consultees and commentators (pre-referral) for the appraisal of Intensity-Modulated Radiotherapy for treatment of Prostate Cancer

12.	Remove the following groups from the matrix: British Liver	NICE Secretariat	Removed	These groups were left over from the previous matrix, so needed to be removed.
	Trust,CORE – The			
	Digestive Disorders			
	Foundation, HALT –			
	Help Against Liver			
	Tumours & Pelican			

Response to comments on the matrix of consultees and commentators (pre-referral) for the appraisal of Intensity-Modulated Radiotherapy for treatment of Prostate Cancer